Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia

Abstract Background Macroprolactinemia is an analytic laboma encountered as a part of prolactin assay. No data are available on the burden of macroprolactinemia in Indians. This study aimed to determine the prevalence and predictors of macroprolactinemia among people with hyperprolactinemia. Methods Consecutive patients detected to have serum prolactin > 18 ng/mL as per the upper reference limit were further screened for macroprolactin by post-polyethylene-glycol (PEG)-precipitation test. Macroprolactinemia was defined as post-PEG recovery of prolactin < 40%. Results The four most common underlying etiologies for the testing of hyperprolactinemia were polycystic ovary syndrome (n = 402; 32.71%), pituitary adenomas (n = 318; 25.87%), drug-induced hyperprolactinemia (n = 224; 18.23%), and infertility (n = 126; 10.25%). A total of 1,229 patients (male:female = 191:1038) having mean age 30.46 ± 10.14 years had hyperprolactinemia, of which 168 (13.7%) were diagnosed to have macroprolactinemia. Macroprolactinemia was significantly higher in females than males (15.03 vs. 6.28%; p < 0.001). Age quartile-based analysis revealed no difference in occurrence of macroprolactinemia. Only 34 patients (2.76%) with macroprolactinemia (< 40% recovery of prolactin post-PEG precipitation) had raised prolactin levels after recovery. These patients primarily had underlying pituitary pathology. Conclusion Macroprolactinemia is not uncommon in people being tested for hyperprolactinemia. We should not hesitate to screen for macroprolactinemia in patients who have incidentally been detected to have hyperprolactinemia.

[1]  Manish Jain,et al.  Prevalence and reproductive manifestations of macroprolactinemia , 2018, Endocrine.

[2]  S. Orešković,et al.  Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. , 2017, Taiwanese journal of obstetrics & gynecology.

[3]  D. Dutta,et al.  Neonatal endocrine labomas - pitfalls and challenges in reporting neonatal hormonal reports , 2017, Indian Pediatrics.

[4]  D. Dutta,et al.  Hyperprolactinemia in Children with Subclinical Hypothyroidism , 2017, Journal of clinical research in pediatric endocrinology.

[5]  D. Dutta,et al.  Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism. , 2016, European journal of internal medicine.

[6]  K. Aisaka,et al.  A possible cause of the variable detectability of macroprolactin by different immunoassay systems , 2016, Clinical chemistry and laboratory medicine.

[7]  G. Lippi,et al.  Macroprolactin: searching for a needle in a haystack? , 2016, Clinical chemistry and laboratory medicine.

[8]  S. Ezzat,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: CLINICAL RELEVANCE OF MACROPROLACTIN IN THE ABSENCE OR PRESENCE OF TRUE HYPERPROLACTINEMIA. , 2015, Endocrine Practice.

[9]  M. Fleseriu,et al.  Challenges and pitfalls in the diagnosis of hyperprolactinemia. , 2014, Arquivos brasileiros de endocrinologia e metabologia.

[10]  A. Lewiński,et al.  Coexistence of macroprolactinaemia and hyperprolactinaemia in women with oligo-/amenorrhoea is associated with high risk of pituitary adenomas , 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[11]  Takashi Adachi,et al.  Possible involvement of matrix metalloproteinase-3 in the pathogenesis of macroprolactinaemia in some patients with rheumatoid arthritis. , 2013, European journal of endocrinology.

[12]  S. Chan,et al.  Importance of screening for macroprolactin in all hyperprolactinaemic sera. , 2013, The Malaysian journal of pathology.

[13]  N. Sachdeva,et al.  Macroprolactinemia in hyperprolactinemic infertile women , 2013, Endocrine.

[14]  A. Shimatsu,et al.  Macroprolactinemia: Diagnostic, Clinical, and Pathogenic Significance , 2012, Clinical & developmental immunology.

[15]  S. Mukhopadhyay,et al.  Panhypopituitarism with empty sella a sequel of pituitary hyperplasia due to chronic primary hypothyroidism , 2012, Indian journal of endocrinology and metabolism.

[16]  D. Dutta,et al.  Endocrine Labomas , 2012, Indian journal of endocrinology and metabolism.

[17]  N. Hattori,et al.  Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers , 2009, Clinical endocrinology.

[18]  Thomas P. Smith,et al.  Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients , 2009, Clinical endocrinology.

[19]  Thomas P. Smith,et al.  Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. , 2008, Clinical chemistry.

[20]  V. Goffin,et al.  Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. , 2007, The Journal of rheumatology.

[21]  C. Inagaki,et al.  Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. , 2006, The Journal of endocrinology.

[22]  A. Leaños-Miranda,et al.  Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia , 2001, Lupus.

[23]  Kane,et al.  Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition , 1999, Clinical endocrinology.

[24]  T. Bjøro,et al.  Frequency of hyperprolactinaemia due to large molecular weight prolactin (150-170 kD PRL). , 1995, Scandinavian journal of clinical and laboratory investigation.